SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
SRX Global (NYSE American: SRXH) signed a definitive agreement to acquire CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings (OTCQB: CERO), via a wholly-owned SPV named CERO 1236 that raises capital directly into the subsidiary without diluting SRX shareholders. The deal is expected to accelerate CER-1236, CERo's engineered T cell therapy for hematologic malignancies, with six patients treated to date in the Phase 1 CERTAIN-T trial and no dose-limiting toxicities observed in the latest cohort. A third cohort screening patients — including MDS and myelofibrosis — will evaluate a planned one billion cells/patient dose.
Key figures
- Drug Name
- CER-1236
- Phase Of Trial
- Phase 1/1b
- Patients treated
- 6
- Third cohort dose
- one billion cells/patient
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.